Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 27771463
Hwang JS, et al. (2016) Upregulation of MKP-7 in response to rosiglitazone treatment ameliorates lipopolysaccharide-induced destabilization of SIRT1 by inactivating JNK. Pharmacol Res 114, 47-55 27771463
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.

S46-p - SIRT1 (mouse)
Modsite: DGPGLGRsPGEPsAA SwissProt Entrez-Gene
Orthologous residues
SIRT1 (human): S47‑p, SIRT1 (mouse): S46‑p, SIRT1 (rat): S46‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
rosiglitazone LPS inhibit treatment-induced increase
GW_9662 rosiglitazone inhibit treatment-induced decrease
LPS, rosiglitazone PPAR-gamma (mouse) decrease PPARG siRNA increase